Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.65 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.64 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.64 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.64 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.60 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.59 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.58 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.58 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | RXRA | P19793 | 2/20 | 0.55 |
| ▸ | RXRB | P28702 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 2/20 | 0.55 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18259890 | 0.90 | RXRA (0.70) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL578461 | 0.88 | MAPT (0.54) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL24848155 | 0.84 | KMT2A (0.69) | ADRB2ADRB1ADRB3ALDH1A1SMN1; SMN2 | |
| SCHEMBL978502 | 0.83 | RAB9A (0.71) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL4059146 | 0.82 | NR4A1 (0.74) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL864308 | 0.82 | HDAC1 (0.61) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL4062398 | 0.82 | MAOB (0.56) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL4839180 | 0.81 | MAPT (0.71) | ADRB2ADRB1ADRB3HTTSMN1; SMN2 | |
| SCHEMBL15189660 | 0.81 | MAOB (0.69) | MAOBNR4A2NR4A1NR4A3PARP10 | |
| SCHEMBL832428 | 0.81 | HDAC1 (0.56) | MAOBNR4A2NR4A1NR4A3PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | BRISTOL MYERS SQUIBB CO (US) | 2023-07-06 | — | — | US | disclosed |
| US-8389564-B2 | Proteasome inhibitors | TRIPHASE RESEARCH AND DEVELOPMENT I CORP. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-8389564-B2 | Proteasome inhibitors | TRIPHASE RESEARCH AND DEVELOPMENT I CORP. (CA) | 2013-03-05 | — | — | US | disclosed |
| US-20120270919-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270919-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2012-10-25 | — | — | US | disclosed |
| US-8227503-B2 | Proteasome inhibitors | NEREUS PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227503-B2 | Proteasome inhibitors | NEREUS PHARMACEUTICALS, INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-20110172285-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-20110172285-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2011-07-14 | — | — | US | disclosed |
| US-7910616-B2 | Proteasome inhibitors | NEREUS PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-7910616-B2 | Proteasome inhibitors | NEREUS PHARMACEUTICALS, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| US-20090298906-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298906-A1 | PROTEASOME INHIBITORS | NEREUS PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| EP-1183251-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2004-02-11 | — | — | EP | disclosed |
| US-6683096-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-01-27 | — | — | US | disclosed |
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-10-10 | — | — | US | disclosed |
| EP-1183251-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | Almirall Prodesfarma, S.A. (ES) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000075130-A1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA, S.A. (ES) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | MAOB 209/4885NR4A2 2140/4885NR4A1 906/4885 |
| US-20230212158-A1 | SMALL MOLECULE INHIBITORS OF GALECTIN-3 | LGALS3, LGALS1, LGALS3BP | MAOB 3506/4885NR4A2 4483/4885NR4A1 4381/4885 |
| US-20120270919-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | MAOB 3837/4885NR4A2 1433/4885NR4A1 1543/4885 |
| US-20090298906-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | MAOB 3837/4885NR4A2 1433/4885NR4A1 1543/4885 |
| US-20110172285-A1 | PROTEASOME INHIBITORS | PSMB1, PSME1, PSME3 | MAOB 3837/4885NR4A2 1433/4885NR4A1 1543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.